Leap Therapeutics
(NASDAQ:LPTX)
$2.21
0.07[3.27%]
At close: Mar 18
$2.21
0[0.00%]
PreMarket: 9:11AM EDT

GET A REPORT ON LPTX SENT RIGHT TO YOUR INBOX

Q4 2023 Earnings were released on Mon Mar 18th, before the market open

Leap Therapeutics Stock (NASDAQ:LPTX), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.
Consensus Rating1
Outperform
Highest Price Target1
$17.50
Lowest Price Target1
$7.00
Consensus Price Target1
$11.38

Analyst Rating Summary1

Analyst Ratings
Nov 23
2
Mar
2
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Baird
HC Wainwright & Co.
Mizuho
Raymond James

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Leap Therapeutics

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
03/19/2024LPTXBuy Now
Leap Therapeutics
$2.21307.24%Baird
Joel Beatty
$11 → $9MaintainsOutperformGet Alert
03/19/2024LPTXBuy Now
Leap Therapeutics
$2.21216.74%HC Wainwright & Co.
Swayampakula Ramakanth
→ $7ReiteratesBuy → BuyGet Alert
11/20/2023LPTXBuy Now
Leap Therapeutics
$2.21442.99%Mizuho
Mara Goldstein
$20 → $12MaintainsBuyGet Alert
11/14/2023LPTXBuy Now
Leap Therapeutics
$2.21691.86%Raymond James
Steven Seedhouse
$18.5 → $17.5MaintainsOutperformGet Alert
08/15/2023LPTXBuy Now
Leap Therapeutics
$2.21804.98%Baird
Joel Beatty
$30 → $20MaintainsOutperformGet Alert
08/15/2023LPTXBuy Now
Leap Therapeutics
$2.21216.74%HC Wainwright & Co.
Swayampakula Ramakanth
$2.5 → $7MaintainsBuyGet Alert
07/13/2023LPTXBuy Now
Leap Therapeutics
$2.21737.1%Raymond James
Steven Seedhouse
$17 → $18.5MaintainsOutperformGet Alert
06/23/2023LPTXBuy Now
Leap Therapeutics
$2.21669.23%Raymond James
Steven Seedhouse
$20 → $17MaintainsOutperformGet Alert
05/16/2023LPTXBuy Now
Leap Therapeutics
$2.2113.12%HC Wainwright & Co.
Swayampakula Ramakanth
→ $25ReiteratesBuy → BuyGet Alert
04/13/2023LPTXBuy Now
Leap Therapeutics
$2.21-9.5%Mizuho
Mara Goldstein
→ $20Reiterates → BuyGet Alert
03/27/2023LPTXBuy Now
Leap Therapeutics
$2.2113.12%HC Wainwright & Co.
Swayampakula Ramakanth
→ $25Reiterates → BuyGet Alert
03/27/2023LPTXBuy Now
Leap Therapeutics
$2.21-9.5%Raymond James
Steven Seedhouse
$25 → $20MaintainsOutperformGet Alert
03/17/2023LPTXBuy Now
Leap Therapeutics
$2.21-9.5%Mizuho
Mara Goldstein
$30 → $20MaintainsBuyGet Alert
01/27/2023LPTXBuy Now
Leap Therapeutics
$2.2135.75%Mizuho
Mara Goldstein
$60 → $30MaintainsBuyGet Alert
01/18/2023LPTXBuy Now
Leap Therapeutics
$2.2113.12%HC Wainwright & Co.
Swayampakula Ramakanth
$40 → $25MaintainsBuyGet Alert
11/11/2022LPTXBuy Now
Leap Therapeutics
$2.2113.12%Raymond James
Steven Seedhouse
$35 → $25MaintainsOutperformGet Alert
08/15/2022LPTXBuy Now
Leap Therapeutics
$2.2158.37%Raymond James
Steven Seedhouse
$30 → $35MaintainsOutperformGet Alert
07/13/2022LPTXBuy Now
Leap Therapeutics
$2.2135.75%Raymond James
Steven Seedhouse
$40 → $30MaintainsOutperformGet Alert
10/04/2021LPTXBuy Now
Leap Therapeutics
$2.21171.49%Mizuho
Mara Goldstein
Initiates → BuyGet Alert

FAQ

Q

What is the target price for Leap Therapeutics (LPTX)?

A

The latest price target for Leap Therapeutics (NASDAQ: LPTX) was reported by Baird on March 19, 2024. The analyst firm set a price target for $9.00 expecting LPTX to rise to within 12 months (a possible 307.24% upside). 12 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Leap Therapeutics (LPTX)?

A

The latest analyst rating for Leap Therapeutics (NASDAQ: LPTX) was provided by Baird, and Leap Therapeutics maintained their outperform rating.

Q

When is the next analyst rating going to be posted or updated for Leap Therapeutics (LPTX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Leap Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Leap Therapeutics was filed on March 19, 2024 so you should expect the next rating to be made available sometime around March 19, 2025.

Q

Is the Analyst Rating Leap Therapeutics (LPTX) correct?

A

While ratings are subjective and will change, the latest Leap Therapeutics (LPTX) rating was a maintained with a price target of $11.00 to $9.00. The current price Leap Therapeutics (LPTX) is trading at is $2.21, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch